Want to see FLNA full AI Analyst Report?
Filana Therapeutics (FLNA) Ratios
Filana Therapeutics Ratios
FLNA's free cash flow for Q2 2026 was $-3.88M. For the 2026 fiscal year, FLNA's free cash flow was decreased by $-21.00K and operating cash flow was $-3.85M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.23 | 0.00 | 9.13 | 29.91 | 19.51 |
| Quick Ratio | 2.23 | 0.00 | 9.13 | 29.91 | 19.51 |
| Cash Ratio | 2.18 | 0.00 | 8.53 | 28.46 | 18.62 |
| Solvency Ratio | -2.05 | 0.00 | -6.74 | -10.27 | -2.48 |
| Operating Cash Flow Ratio | -0.74 | 0.00 | -5.78 | -10.97 | -2.41 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 53.76M | $ 0.00 | $ 115.44M | $ 203.93M | $ 231.62M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.59 | 0.00 | 1.10 | 1.03 | 1.05 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Net Debt to EBITDA | 1.06 | 0.00 | 1.16 | 2.55 | 7.21 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 95.37% | 17.21% | 91.75% | 95.28% | 98.53% |
| Return on Assets (ROA) | -76.86% | 0.00% | -64.10% | -32.47% | -12.14% |
| Return on Equity (ROE) | -122.27% | 0.00% | -70.72% | -33.51% | -12.75% |
| Return on Capital Employed (ROCE) | -128.00% | 0.00% | -77.08% | -35.13% | -12.93% |
| Return on Invested Capital (ROIC) | -128.00% | 0.00% | -77.08% | -35.12% | -12.92% |
| Return on Tangible Assets | -76.86% | 0.00% | -64.18% | -32.55% | -12.19% |
| Earnings Yield | -91.88% | -25.63% | -72.00% | -44.94% | -13.17% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.15 | 0.00 | 8.46 | 16.94 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2494.56 | 0.00 | -43.16 | -21.55 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2494.56 | 0.00 | 43.16 | 21.55 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.67 | 0.00 | -1.96 | -1.93 | -0.77 |
| Free Cash Flow Per Share | -0.68 | 0.00 | -1.97 | -2.00 | -1.33 |
| Dividend Paid and CapEx Coverage Ratio | -55.51 | 0.00 | -198.13 | -28.58 | -1.36 |
| Capital Expenditure Coverage Ratio | -55.51 | 0.00 | -198.13 | -28.58 | -1.36 |
| Operating Cash Flow Coverage Ratio | 0.00 | 0.00 | 0.00 | -557.65 | -127.95 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -33.16% | 0.00% | -61.06% | -47.29% | -21.31% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.09 | -3.87 | -1.39 | -2.23 | -7.59 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.33 | 0.00 | 0.98 | 0.75 | 0.97 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.02 | 0.00 | -1.64 | -2.11 | -4.69 |
| Price-to-Operating Cash Flow Ratio | -3.07 | 0.00 | -1.65 | -2.19 | -8.14 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | 0.05 | -0.05 | -0.02 | -0.03 |
| Enterprise Value Multiple | -0.04 | 0.00 | -0.13 | 0.40 | -0.39 |
| Enterprise Value | 3.51M | 0 | 13.89M | -31.22M | 12.69M |
| EV to EBITDA | -0.04 | 0.00 | -0.13 | 0.40 | -0.39 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -0.11 | 0.00 | -0.17 | 0.39 | -0.24 |
| EV to Operating Cash Flow | -0.11 | 0.00 | -0.17 | 0.40 | -0.42 |
| Tangible Book Value Per Share | 1.54 | 0.00 | 3.27 | 5.64 | 6.42 |
| Shareholders’ Equity Per Share | 1.54 | 0.00 | 3.28 | 5.66 | 6.44 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.88 | -0.53 | -2.32 | -1.90 | -0.82 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.17 | 0.92 | 0.95 | 0.99 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.35 | 0.00 | 0.84 | 1.02 | 0.93 |
Currency in USD
